Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 20;39(30):3411-3412.
doi: 10.1200/JCO.21.01430. Epub 2021 Sep 7.

Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma

Thomas Powles  1 , Daniel P Petrylak  1 , Jonathan E Rosenberg  1
Affiliations
Comment

Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma

Thomas Powles et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Thomas PowlesConsulting or Advisory Role: Astellas Pharma, Inc, AstraZeneca, Bristol Myers Squibb (BMS), Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, SeagenResearch Funding: Astellas Pharma, Inc, AstraZeneca, Bristol Myers Squibb (BMS), Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, SeagenTravel, Accommodations, Expenses: AstraZeneca, Ipsen, MSD, Pfizer, Roche Daniel P. PetrylakStock and Other Ownership Interests: Bellicum Pharmaceuticals, TYMEConsulting or Advisory Role: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas Pharma, Inc, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen, Lilly, Mirati Therapeutics, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seagen, UrogenResearch Funding: Ada Cap (Advanced Accelerator Applications) (Inst), Agensys (Inst), Astellas Medivation (Inst), AstraZeneca (Inst), Bayer (Inst), BioXcel Therapeutics (Inst), Bristol-Myers Squibb (Inst), Clovis Oncology (Inst), Eisai (Inst), Endocyte (Inst), Genentech (Inst), Gilead Sciences (Inst), Innocrin Pharma (Inst), Lilly (Inst), MedImmune (Inst), Medivation (Inst), Merck (Inst), Mirati Therapeutics (Inst), Novartis (Inst), Pfizer (Inst), Progenics (Inst), Replimune (Inst), Roche (Inst), Sanofi (Inst), Seagen (Inst)Expert Testimony: Celgene, Sanofi Jonathan E. RosenbergStock and Other Ownership Interests: IlluminaHonoraria: Clinical Care Options, ClinicalMind, Intellisphere, Medscape, Peerview, Physicans' Education Resource, Research To Practice, UpToDateConsulting or Advisory Role: Adicet Bio, Astellas Pharma, AstraZeneca/MedImmune, Bayer, BioClin Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Fortress Biotech, GlaxoSmithKline, Immunomedics, Janssen Oncology, Lilly, Merck, Mirati Therapeutics, Pfizer/EMD Serono, Pharmacyclics, Roche/Genentech, Seagen, QED Therapeutics, Western OncolyticsResearch Funding: Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), Genentech/Roche (Inst), Seagen (Inst), QED Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity (Inst)No other potential conflicts of interest were reported.

Comment in

  • Reply to T. Powles et al.
    Tagawa ST, Grivas P. Tagawa ST, et al. J Clin Oncol. 2021 Oct 20;39(30):3412-3413. doi: 10.1200/JCO.21.01673. Epub 2021 Sep 7. J Clin Oncol. 2021. PMID: 34491818 No abstract available.

Comment on

MeSH terms

LinkOut - more resources